GlassScriptPhysician profile
Jason Abdallah
NPI 1093071565
$3,483.27
in general payments reported to CMS, 2019-2025
21 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $415 · 2021: $184 · 2022: $286 · 2023: $269 · 2024: $710 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $51.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.67 |
| Education | $51.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.89 | 2019-2025 | Mavyret, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $488.25 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $188.32 | 2019-2025 | |
| Medtronic, INC. | $166.93 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $99.64 | 2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.83 | 2019-2023 | Xifaxan |
| Qol Medical, LLC | $75.61 | 2024-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $74.20 | 2020-2022 | |
| Gilead Sciences, INC. | $67.25 | 2020-2025 | Livdelzi |
| Shionogi INC | $46.82 | 2019-2020 | |
| Ardelyx, INC. | $40.96 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $35.56 | 2023 | Bridion |
| Endo Pharmaceuticals INC. | $31.93 | 2020 | |
| Phathom Pharmaceuticals, INC. | $26.18 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $25.27 | 2025 | Rezdiffra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.35 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $22.00 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $17.50 | 2024 | |
| Celgene Corporation | $14.89 | 2023 | Zeposia |
| Evoke Pharma, INC. | $13.57 | 2024 | |
| Janssen Biotech, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Abdallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.